1	21 NCAC 32M .0109 is amended,	with changes,	as published in 35:18 NCR 2061-2062 as follows:
---	-------------------------------	---------------	---

\mathbf{a}
4

2						
3	21 NCAC 32M	.0109	PRESCRIBING AUTHORITY			
4	(a) The prescrib	(a) The prescribing stipulations contained in this Rule apply to writing prescriptions and ordering the administration				
5	of medications.					
6	(b) Prescribing	(b) Prescribing and dispensing stipulations are as follows:				
7	(1)	Drugs and devices that may be prescribed by the nurse practitioner in each practice site shall be				
8		included in the collaborative practice agreement as outlined in Rule .0110(2) of this Section.				
9	(2)	Controlled Substances (Schedules II, IIN, III, IIIN, IV, V) defined by the State and Federal				
10		Contro	blled Substances Acts may be procured, prescribed, or ordered as established in the			
11		collab	orative practice agreement, providing all of the following requirements are met:			
12		(A)	the nurse practitioner has an assigned DEA number that is entered on each prescription for			
13			a controlled substance;			
14		(B)	refills may be issued consistent with Controlled Substance laws and regulations; and			
15		(C)	the primary supervising physician(s) possesses the same shall possess a schedule(s) of			
16			controlled substances as equal to or greater than the nurse practitioner's DEA registration.			
17	(3)	The n	urse practitioner may prescribe a drug or device not included in the collaborative practice			
18		agreer	nent only as follows:			
19		(A)	upon a specific written or verbal order obtained from a primary or back-up supervising			
20			physician before the prescription or order is issued by the nurse practitioner; and			
21		(B)	the written or verbal order as described in Part (b)(3)(A) of this Rule shall be entered into			
22			the patient record with a notation that it is issued on the specific order of a primary or back-			
23			up supervising physician and signed by the nurse practitioner and the physician.			
24	(4)	Each p	prescription shall be noted on the patient's chart and include the following information:			
25		(A)	medication and dosage;			
26		(B)	amount prescribed;			
27		(C)	directions for use;			
28		(D)	number of refills; and			
29		(E)	signature of nurse practitioner.			
30	(5)	Prescr	iption Format:			
31		(A)	All prescriptions issued by the nurse practitioner shall contain the supervising physician(s)			
32			name, the name of the patient, <u>patient</u> and the nurse practitioner's name, <u>name and</u>			
33			telephone number, and approval number. <u>number:</u>			
34		(B)	The nurse practitioner's assigned DEA number shall be written on the prescription form			
35			when a controlled substance is prescribed as defined in Subparagraph (b)(2) of this Rule.			
36	(6)	A nur	se practitioner shall not prescribe controlled substances, as defined by the State and Federal			
37		Controlled Substances Acts, for the following:				

1		(A)	nurse practitioner's own use;		
2		(B)	nurse practitioner's supervising physician;		
3		(C)	a member of the nurse practitioner's immediate family, which shall mean: mean a:		
4			(i)	spouse;	
5			(ii)	parent;	
6			(iii)	child;	
7			(iv)	sibling;	
8			(v)	parent-in-law;	
9			(vi)	son or daughter-in-law;	
10			(vii)	brother or sister-in-law;	
11			(viii)	step-parent;	
12			(ix)	step-child; or	
13			(x)	step-siblings;	
14		(D)	any otl	her person living in the same residence as the licensee; or	
15		(E)	anyone	e with whom the nurse practitioner is having a sexual physical, sexual, [and/or] or	
16			[<mark>emoti</mark>	onal] emotionally intimate relationship.	
17	(c) The nurse p	oractition	er may ol	otain approval to dispense the drugs and devices other than samples included in the	
18	collaborative pr	actice ag	reement	for each practice site from the Board of Pharmacy, and dispense in accordance with	
19	21 NCAC 46 .1	703 that	is hereby	incorporated by reference including subsequent amendments.	
20					
21	History Note:	Authority G.S. <u>90-5.1(a)(3); 90-18(c)(14);</u> 90-18.2;			
22		Eff. February 1, 1991;			
23		Recodified from 21 NCAC 32M .0106 Eff. January 1, 1996;			
24		Amended Eff. December 1, 2012; April 1, 2011; November 1, 2008; August 1, 2004; May 1, 1999;			
25		January 1, 1996; September 1, 1994; March 1, 1994;			
26		Pursuant to G.S. 150B-21.3A rule is necessary without substantive public interest Eff. March 1,			
27		2016;			
28		Amended Eff. <u>August 1, 2021;</u> March 1, 2017.			